4/A: Mereo BioPharma Executive Corrects Filing on ADS Ownership

Sentiment:

SEC Filing


Alexandra Hughes-Wilson, a Mereo BioPharma executive, amended a previous SEC filing to reflect that a reported transaction involving American Depositary Shares (ADS) was canceled before settlement.

Summary

  • Alexandra Hughes-Wilson, Chief Patient Access and Commercial Planning at Mereo BioPharma Group plc, filed an amended Form 4 with the SEC on June 11, 2024.
  • This amendment corrects a previous filing from May 23, 2024, regarding changes in beneficial ownership of the company's securities.
  • The original transactions reported on May 23, 2024, were canceled in their entirety before settlement, meaning no shares were actually transferred.
  • The filing indicates that Hughes-Wilson directly owns 7,650 American Depositary Shares (ADS), with each ADS representing five ordinary shares of Mereo BioPharma Group plc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

SEC filings related to changes in beneficial ownership are a routine part of corporate governance and provide transparency to investors regarding the holdings of company insiders.

Key Dates

DateDescription
05/22/2024Date of earliest transaction
05/23/2024Date of original filing that was amended
06/11/2024Date of amended filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.